JP2009523456A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523456A5
JP2009523456A5 JP2008551611A JP2008551611A JP2009523456A5 JP 2009523456 A5 JP2009523456 A5 JP 2009523456A5 JP 2008551611 A JP2008551611 A JP 2008551611A JP 2008551611 A JP2008551611 A JP 2008551611A JP 2009523456 A5 JP2009523456 A5 JP 2009523456A5
Authority
JP
Japan
Prior art keywords
treating
drug
vasopressin
subject
gene sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000111 external-priority patent/WO2007085087A1/en
Publication of JP2009523456A publication Critical patent/JP2009523456A/ja
Publication of JP2009523456A5 publication Critical patent/JP2009523456A5/ja
Pending legal-status Critical Current

Links

JP2008551611A 2006-01-24 2007-01-24 重篤な被検体の被検体結果の指標としてのバソプレシン経路多型 Pending JP2009523456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76132806P 2006-01-24 2006-01-24
US79515706P 2006-04-27 2006-04-27
PCT/CA2007/000111 WO2007085087A1 (en) 2006-01-24 2007-01-24 Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects

Publications (2)

Publication Number Publication Date
JP2009523456A JP2009523456A (ja) 2009-06-25
JP2009523456A5 true JP2009523456A5 (enExample) 2010-03-11

Family

ID=38308805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551611A Pending JP2009523456A (ja) 2006-01-24 2007-01-24 重篤な被検体の被検体結果の指標としてのバソプレシン経路多型

Country Status (6)

Country Link
EP (1) EP1984546A4 (enExample)
JP (1) JP2009523456A (enExample)
AU (1) AU2007209725A1 (enExample)
CA (1) CA2638773A1 (enExample)
MX (1) MX2008009654A (enExample)
WO (1) WO2007085087A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008303928A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
JP2010538991A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのsfllr−ohおよびムラミルジペプチドの使用
WO2009033667A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP5785942B2 (ja) 2009-06-29 2015-09-30 ルミネックス コーポレーション ヘアピンコンフォメーションを有するキメラプライマーおよびその使用法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2897959B2 (ja) * 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US6727063B1 (en) * 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes
WO2003097877A1 (fr) * 2002-05-17 2003-11-27 Riken Procede de detection d'un polymorphisme genique
US20040033582A1 (en) * 2002-06-03 2004-02-19 Manling-Ma Edmonds Human single nucleotide polymorphisms
JP2006520199A (ja) * 2003-03-19 2006-09-07 ザ ユニバーシティ オブ ブリティッシュ コロンビア 患者結果の指標として有用なプラスミノーゲンアクチベーターインヒビター‐1(pai−1)ハプロタイプ
WO2005038462A1 (en) * 2003-10-21 2005-04-28 Suntory Limited Method for prognostic evaluation of carcinoma using anti-p-lap antibody
AU2005219473A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Toll-like receptor 2 (TLR-2) haplotypes predict outcome of patients
AU2005219472A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Thrombomodulin (THBD) haplotypes predict outcome of patients
CA2479968A1 (en) * 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome

Similar Documents

Publication Publication Date Title
JP2011511805A5 (enExample)
JP2009519986A5 (enExample)
JP2009513660A5 (enExample)
JP2008245635A5 (enExample)
EP2210092A4 (en) SEMAPHORINE COMPREHENSIVE COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO ANGIOGENESIS AND SELECTION PROCEDURES THEREFOR
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP2011525990A5 (enExample)
JP2007517055A5 (enExample)
CL2007001132A1 (es) Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP2007522094A5 (enExample)
WO2008008433A3 (en) Substituted acylanilides and methods of use thereof
WO2008050148A3 (en) Therapy for liver disease
JP2015504870A5 (enExample)
NO20092398L (no) Krystallinske former av solvatisert ilaprazol
JP2013539454A5 (enExample)
GEP20094851B (en) Selective androgen receptor modulators and methods of use thereof
JP2009535036A5 (enExample)
JP2016538270A5 (enExample)
EP2271929A4 (en) USE OF NITRATED LIPIDS FOR THE TREATMENT OF LIPID FAILURES AND FATIBILITY AND SUFFERING IN CONNECTION WITH LIPIDES AND FATIBILITY
NO20084458L (no) IL-8-reseptorantagonister
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
JP2017511377A5 (enExample)
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途